Finally, this analysis did not evaluate the effects of teneligliptin in combination with another therapeutic agent for type 2 diabetes such as insulin, thiazolidinedione, and sodium glucose co-transporter 2 inhibitors. The gene discussed is INS; the disease is type 2 diabetes mellitus.